文献速递骨软组织肉瘤与黑色素瘤

儿童及青少年上皮样肉瘤的临床特征与结局:儿童肿瘤协作组与欧洲儿童软组织肉瘤研究组前瞻性临床试验分析

Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials.
PubMed 文献 · Eur J Cancer · 2019-04-05

基于2005年7月至2015年11月两项国际前瞻性临床试验的子集分析,纳入63例30岁以下上皮样肉瘤患者,按肿瘤直径、组织学分级、手术范围及有无转移行风险适应治疗。低危患者5年生存率为86.4%,中危为63.5%,高危为0%。

要点

  • 低危上皮样肉瘤患者经充分切除后多无须辅助治疗即结局良好。
  • 大肿瘤、高级别、侵袭性、切除不充分及转移提示预后较差。
  • 中高危患者需要更有效的治疗。

核心结论

  • 多数低危上皮样肉瘤患者经充分切除后不给予辅助治疗亦结局良好。
  • 肿瘤体积大、组织学分级高、肿瘤具侵袭性、切除不充分及转移提示高危患者结局更差,此类患者需要更有效的治疗。

研究设计与样本

  • 对2005年7月至2015年11月两项国际前瞻性临床试验中入组的30岁以下上皮样肉瘤患者进行子集分析。
  • 风险适应治疗依据肿瘤直径、组织学分级、手术范围及有无转移制定,所有患者均接受手术±放疗,中危/高危患者加用异环磷酰胺/多柔比星化疗。

主要发现

  • 共63例上皮样肉瘤患者符合条件,中位年龄13.1岁,52%为男性。
  • 68%为肢体病变,中位肿瘤直径3.5 cm,56%为高级别组织学分级,14%有淋巴结转移,14%有远处转移。
  • 34例低危患者接受手术(n=30)或手术/放疗(n=4);16例中危和13例高危患者接受化疗±手术±放疗。
  • 接受新辅助治疗的22例患者中11例(50%)观察到部分缓解。
  • 事件为局部复发(n=10)和远处复发(n=15);低危、中危和高危患者的估计5年生存率分别为86.4%、63.5%和0%。

关键数值与推荐

  • 风险分层依据肿瘤直径、组织学分级、手术范围和有无转移,低危组34例仅手术或手术/放疗。
  • 中危16例和高危13例接受化疗±手术±放疗,新辅助治疗部分缓解率为11/22(50%)。
  • 低危、中危、高危患者估计5年生存率分别为86.4%、63.5%和0%。
  • 无转移患者中,区域淋巴结受累、侵袭性肿瘤、高级别和切除范围较小与无事件生存相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出上皮样肉瘤的临床特征、最佳治疗和结局数据有限,且多为回顾性研究。
  • 原文结论指出高危上皮样肉瘤患者需要更有效的治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on the clinical features, optimal treatment and outcomes of paediatric patients with epithelioid sarcoma (ES) are limited and mostly retrospective. METHODS: A subset analysis of ES patients < 30 years of age enrolled on two international prospective clinical trials conducted between 7/2005 and 11/2015 was performed. Risk-adapted therapy was based on tumour diameter, histologic grade, extent of surgery and presence/absence of metastases and included surgery ± radiotherapy for all patients with the addition of ifosfamide/doxorubicin chemotherapy for intermediate-/high-risk patients. Response to therapy, event-free and overall survival and pattern and predictors of treatment failure were evaluated. RESULTS: Sixty-three ES patients (median age 13.1 years, 52% male) were eligible. Clinical features included the following: 68% extremity, median tumour diameter 3.5 cm, 56% high histologic grade, 14% nodal metastases, 14% distant metastases. Thirty-four low-risk patients underwent surgery (n = 30) or surgery/radiotherapy (n = 4); 16 intermediate-risk and 13 high-risk patients received chemotherapy ± surgery ± radiotherapy. Partial response was observed in 11/22 (50%) patients receiving neoadjuvant therapy. Events were local recurrence (n = 10) and distant recurrence (n = 15); estimated 5-year survival was 86.4%, 63.5% and 0%, respectively, for low-, intermediate- and high-risk patients. Locoregional nodal involvement, invasive tumour, high grade and lesser extent of resection predicted event-free survival in patients without metastases. CONCLUSIONS: Most low-risk ES patients who have undergone an adequate resection fare well without adjuvant therapy. Large tumour size, high histologic grade, tumour invasiveness, inadequate tumour resection and metastatic disease predict poorer outcomes in higher risk ES patients, for whom more effective therapies are needed. CLINICAL TRIAL REGISTRATION: COG ARST0332: ClinicalTrials.gov Identifier NCT00346164, EpSSG NRSTS 2005: European Union Drug Regulating Authorities Clinical Trials No. 2005-001139-31.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Spunt SL, Francotte N, De Salvo GL, et al. Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials. Eur J Cancer. 2019. PMID: 30954717. doi:10.1016/j.ejca.2019.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。